Reduction of facial pigmentation of melasma by topical lignin peroxidase: A novel fast-acting skin-lightening agent

被引:19
作者
Zhong, Shao-Min [1 ]
Sun, Nan [1 ]
Liu, Hui-Xian [1 ]
Niu, Yue-Qing [1 ]
Wu, Yan [1 ]
机构
[1] Peking Univ, Dept Dermatol, Hosp 1, Beijing 100034, Peoples R China
关键词
lignin peroxidase; melanin; melasma; skin lightening; emulsions; statistics; GUIDELINES; TRIALS;
D O I
10.3892/etm.2014.2118
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The aim of the present study was to evaluate the efficacy and safety of lignin peroxidase (LIP) as a skin-lightening agent in patients with melasma. A self-controlled clinical study was performed in 31 women who had melasma on both sides of the face. This study involved 8 weeks of a full-face product treatment. The skin color was measured at days 0, 7, 28 and 56 using a chromameter on the forehead and cheeks. Standardized digital photographic images of each side of the face of all subjects were captured by a complexion analysis system. Clinical scores of the pigmentation were determined by two dermatologists. After using the LIP whitening lotion for 7 days, the luminance (L*) values of the melasma and the normal skin were significantly increased from baseline. The L* values continued to increase at days 28 and 56. The melasma area severity index (MASI) score was statistically decreased after 28 days of treatment. No treatment-related adverse events were observed. LIP whitening lotion was able to eliminate the skin pigmentation after 7 days of treatment, and provides a completely innovative approach to rapid skin lightening. The LIP whitening lotion exhibited good compatibility and was well tolerated.
引用
收藏
页码:341 / 344
页数:4
相关论文
共 14 条
[1]  
[Anonymous], 2006, SKIN BLEACH DRUG PRO
[2]  
[Anonymous], 1993, APPL ENVIRON MICROB, V59, P4010
[3]   Melanosome degradation: Fact or fiction [J].
Borovansky, J ;
Elleder, M .
PIGMENT CELL RESEARCH, 2003, 16 (03) :280-286
[4]   Association of emblica, licorice and belides as an alternative to hydroquinone in the clinical treatment of melasma [J].
Costa, Adilson ;
Moises, Thais Abdalla ;
Cordero, Tatiana ;
Tiburcio Alves, Caroline Romanelli ;
Marmirori, Juliana .
ANAIS BRASILEIROS DE DERMATOLOGIA, 2010, 85 (05) :613-620
[5]   The melanogenesis and mechanisms of skin-lightening agents - existing and new approaches [J].
Gillbro, J. M. ;
Olsson, M. J. .
INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, 2011, 33 (03) :210-221
[6]   WHO GUIDELINES FOR GOOD CLINICAL-PRACTICE (GCP) FOR TRIALS ON PHARMACEUTICAL PRODUCTS - RESPONSIBILITIES OF THE INVESTIGATOR [J].
IDANPAANHEIKKILA, JE .
ANNALS OF MEDICINE, 1994, 26 (02) :89-94
[7]   Guidelines for clinical trials in melasma [J].
Pandya, A. ;
Berneburg, M. ;
Ortonne, J. -P. ;
Picardo, M. .
BRITISH JOURNAL OF DERMATOLOGY, 2006, 156 :21-28
[8]   Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method [J].
Pandya, Amit G. ;
Hynan, Linda S. ;
Bhore, Rafia ;
Riley, Fransell Copeland ;
Guevara, Ian L. ;
Grimes, Pearl ;
Nordlund, James J. ;
Rendon, Marta ;
Taylor, Susan ;
Gottschalk, Ronald W. ;
Agim, Nnenna G. ;
Ortonne, Jean-Paul .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (01) :78-83
[9]   Time course of ultraviolet-induced skin reactions evaluated by two different reflectance spectrophotometers:: DermaSpectrophotometer® and Minolta spectrophotometer CM-2002® [J].
Park, SB ;
Huh, CH ;
Choe, YB ;
Youn, JI .
PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE, 2002, 18 (01) :23-28
[10]  
Rajaratnam R, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003583.pub2